27th PAGE Meeting

Montreux - Switzerland
29 May - 1 June, 2018

View abstracts

Home / 2018 – Montreux – Switzerland / Abstracts

← Back to filters

Abstracts (20)

I-09Yucheng Sheng

Item response theory modelling of motor scores to investigate feasibility of reducing proof-of-concept trial for Parkinson’s disease

Wednesday 10:10-11:40

I-11Alena Simalatsar

Personalised delivery rate computation for intravenously administered anesthetic using Kalman filter

Wednesday 10:10-11:40

I-44Michiel Van Esdonk

Population pharmacokinetic/pharmacodynamic analysis of multiple nociceptive pain models following a single oral pregabalin dose administration to healthy subjects

Wednesday 10:10-11:40

I-78Xiao Zhu

Application of pharmacometrics to stimulus response models to describe signalling profiles of the cannabinoid-1 receptor

Wednesday 10:10-11:40

II-27Anais Glatard

Population pharmacokinetic model of amisulpride for individual dosing in psychiatric patients

Wednesday 15:50-17:20

II-61Siv Jonsson

Sample size for detection of drug effect using item level and total score models for Unified Parkinson’s Disease Rating Scale data

Wednesday 15:50-17:20

III-04Jae Eun Ahn

Pharmacokinetic/Pharmacodynamic effects of PF-06648671, a novel gamma secretase modulator following single and multiple dose administration in healthy volunteers

Thursday 09:55-11:30

III-23Agnieszka Bienert

Pharmacokinetics of dexmedetomidine in elderly patients undergoing sedation after abdominal aortic surgery.

Thursday 09:55-11:30

III-34Thierry Buclin

Closed-loop control for propofol administration during anesthesia based on real-time concentration measurement: a simulation study

Thursday 09:55-11:30

III-54Valerie Cosson

Population PKPD modeling of RO7046015 (PRX002/RG7935), an Anti--Synuclein Monoclonal Antibody for the treatment of Parkinson’s Disease

Thursday 09:55-11:30

III-57Ailing Cui

Quantitative Predictive Models for the Degree of Disability After Acute Ischemic Stroke

Thursday 09:55-11:30

III-62Olivier David

A PKPD model describing the amyloid precursor protein (APP) derived peptides in subjects receiving CNP520, a BACE-1 inhibitor.

Thursday 09:55-11:30

III-69Oleg Demin

Simulations of tau-targeted therapies using quantitative systems pharmacology model of tau pathology

Thursday 09:55-11:30

IV-01Brigitte Lacroix

A quantitative framework integrating exposure, efficacy, receptor occupancy and tolerability to propose evidence-based dose regimens for padsevonil

Thursday 15:10-16:40

IV-06Woo Yul Lee

A population pharmacodynamic model of combination antidepressant therapy in depression

Thursday 15:10-16:40

IV-09Giulia Lestini

Two-step modelling approach of time to event and cognitive decline to inform Alzheimer’s disease prevention trials

Thursday 15:10-16:40

IV-10Leticia Arrington

A Model Based Meta-Analysis (MBMA) to support development of medicines for treatment of DPN, PHN and Fibromyalgia.

Thursday 15:10-16:40

IV-25Tomomi Matsuura

Clinical validation of a quantitative systems pharmacology (QSP) model for nerve-growth-factor (NGF) therapies

Thursday 15:10-16:40

IV-33Denise Morris

Population Pharmacokinetic Modeling of Fremanezumab in Support of Phase 3 Development for Patients with Migraine

Thursday 15:10-16:40

IV-59Etienne Pigeolet

Modeling of amyloid accumulation in subjects at risk of Alzheimer’s disease under BACE inhibition treatment.

Thursday 15:10-16:40